ONCY ONCOLYTICS BIOTECH INC

Nasdaq oncolyticsbiotech.com


$ 0.93 $ -0.17 (-15.45 %)    

Tuesday, 04-Nov-2025 13:54:02 EST
QQQ $ 621.51 $ -1.71 (-0.27 %)
DIA $ 470.42 $ 0.06 (0.01 %)
SPY $ 676.11 $ -0.05 (-0.01 %)
TLT $ 89.93 $ 0.14 (0.16 %)
GLD $ 362.49 $ -1.11 (-0.31 %)
$ 1.09
$ 1.10
$ 0.93 x 4,750
$ 0.93 x 100
$ 0.92 - $ 1.10
$ 0.33 - $ 1.51
1,269,461
na
87.22M
$ 1.07
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 oncolytics-biotech-plans-move-from-canada-to-us-with-proposed-domestication-to-nevada

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company ...

 oncolytics-biotech-files-for-common-stock-offering-of-50m

- SEC Filing

 oncolytics-biotech-reports-pelareorep-boosts-survival-in-colorectal-cancer-patients

Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company ...

 oncolytics-biotech-files-for-mixed-shelf-offering-of-up-to-150m

-SEC Filing

 lake-street-initiates-coverage-on-oncolytics-biotech-with-buy-rating-announces-price-target-of-7

Lake Street analyst Chad Messer initiates coverage on Oncolytics Biotech (NASDAQ:ONCY) with a Buy rating and announces Price...

 oncolytics-biotech-q2-eps-005-beats-010-estimate

Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(...

Core News & Articles

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherap...

 oncolytics-biotech-initiated-regulatory-discussions-with-fda-for-potential-registration-enabled-study-in-first-line-pancreatic-cancer

Clear regulatory path and strong survival data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) support accele...

 oncolytics-biotech-presents-aggregated-translational-data-for-pelareorep

Integrated biomarker analyses confirm viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes af...

Core News & Articles

Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, ...

Core News & Articles

Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responsesNew analys...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION